Inhibiting "anchor" molecule in stem cells may improve marrow transplant process

Share this article:

The safety and efficiency of bone marrow transplants may improve due to the discovery of a rare molecule that establishes blood stem cells in their niche within the bone marrow.

The molecule—Robo4—is found only in the hematopoietic stem cells and in the endothelial cells of blood vessels. According to the new study findings, published in Cell Stem Cell (2011;8:72-83), hematopoietic stem cells—the key components in bone marrow transplants—use Robo4 to anchor themselves in the bone marrow where they reside.

In an increasingly common alternative to traditional bone marrow transplants, repeated drug injections are administered to usher stem cells away from bone marrow and into the bloodstream, from which they can be harvested and eventually groomed into different types of cells. The Robo4 discovery, however, creates an opportunity to find agents that can block the molecule in a safer and more effective fashion.

“If we can get specific and efficient inhibition of Robo4, we might be able to mobilize the hematopoietic stem cells to the blood more efficiently,” explained E. Camilla Forsberg, an assistant professor of biomolecular engineering at University of California–Santa Cruz, in a statement describing her team's work.

 

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters


What is this?

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Fewer cardiac scans in low-risk childhood cancer survivors can safely reduce costs ...

A less frequent screening schedule would both reduce health care charges and still protect low-risk childhood cancer survivors from heart ailments caused by drug therapy, according to recently published findings.

Everolimus does not improve overall survival of advanced liver cancer

Despite strong preclinical data, the drug everolimus failed to improve overall survival in patients with advanced liver cancer, compared to placebo, according to a study.

Presence of uterine cancers examined among women at the time of hysterectomy ...

Among women undergoing a minimally invasive hysterectomy using electric power morcellation, uterine cancers were present in 27 per 10,000 women at the time of the procedure, according to a new study.